Vertex to seek US approval after promising late-stage results for kidney drug

By Kamal Choudhury March 9 (Reuters) - Vertex Pharmaceuticals said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage trial, putting the company on track to seek U.S. approval by the end of this month. Shares of the company were up about 7% in extended trading. The drug, povetacicept, is being developed to treat patients with IgA nephropathy, a